GSK

LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial

Retrieved on: 
пятница, июня 14, 2024
Antoni van Leeuwenhoekziekenhuis, GSK, Research, Immunotherapy, Cancer, Clinical trial, Senior, Roche, EMBO Reports, Netherlands Cancer Institute, Neoplasm, NKI, Doctor of Philosophy, MSI, Pharmaceutical industry

PASADENA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced a collaboration with Roche and the Netherlands Cancer Institute (NKI) to conduct a new clinical trial in immune therapy unresponsive (MSI Low) metastatic colon cancer.

Key Points: 
  • Clinical trial to test recent findings that show LIXTE’s lead clinical compound,
    PASADENA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc .
  • (“LIXTE” or the “Company”) ( Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced a collaboration with Roche and the Netherlands Cancer Institute (NKI) to conduct a new clinical trial in immune therapy unresponsive (MSI Low) metastatic colon cancer.
  • As part of the new clinical trial, listed as NCT06012734 at clinicaltrials.gov , LIXTE will provide its lead compound, LB-100, and Roche will provide atezolizumab (Tecentriq®, a PD-L1 inhibitor) through the imCORE Network, an academic-industry collaboration that aims to accelerate cancer immunotherapy research through institution-sponsored studies.
  • “This is an exciting new clinical trial,” said Neeltje Steeghs, M.D., Ph.D., medical oncologist from NKI and Antoni van Leeuwenhoek Hospital, who is serving as principal investigator of the trial.

LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial

Retrieved on: 
пятница, июня 14, 2024
GSK, Immunotherapy, Cancer, Clinical trial, Senior, Roche, EMBO Reports, Netherlands Cancer Institute, Neoplasm, NKI, Doctor of Philosophy, MSI, Pharmaceutical industry

PASADENA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced a collaboration with Roche and the Netherlands Cancer Institute (NKI) to conduct a new clinical trial in immune therapy unresponsive (MSI Low) metastatic colon cancer.

Key Points: 
  • Clinical trial to test recent findings that show LIXTE’s lead clinical compound,
    PASADENA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc .
  • (“LIXTE” or the “Company”) ( Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced a collaboration with Roche and the Netherlands Cancer Institute (NKI) to conduct a new clinical trial in immune therapy unresponsive (MSI Low) metastatic colon cancer.
  • As part of the new clinical trial, listed as NCT06012734 at clinicaltrials.gov , LIXTE will provide its lead compound, LB-100, and Roche will provide atezolizumab (a PD-L1 inhibitor) and financial support.
  • “This is an exciting new clinical trial,” said Neeltje Steeghs, M.D., Ph.D., medical oncologist from the Netherlands Cancer Institute, who is serving as principal investigator of the trial.

Vera Therapeutics Appoints Christy J. Oliger to Board of Directors

Retrieved on: 
вторник, июня 11, 2024
Acquisition, Bristol Myers Squibb, GSK, Patient, IgA nephropathy, Reata Pharmaceuticals, Therapy, Economics, Biogen, Roche, University, Dermatology, Genentech, Neurology

BRISBANE, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Christy J. Oliger to its board of directors, effective June 7, 2024.

Key Points: 
  • BRISBANE, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Christy J. Oliger to its board of directors, effective June 7, 2024.
  • Ms. Oliger brings over 30 years of experience in the biopharmaceutical industry, including being recognized for building highly effective teams and leading significant commercial product launches.
  • “We are delighted to welcome Christy to our Board during this important period in Vera’s history.
  • Ms. Oliger currently serves on multiple public company boards, including Karyopharm Therapeutics, Replimune Group, and LAVA Therapeutics.

Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries

Retrieved on: 
вторник, июня 11, 2024
EVP, Health, Genetic testing, GSK, Patient, Innovation, Myriad Genetics, Doctor of Philosophy, Genetics, HRD, MYGN, Myriad, Ovarian cancer, Medicine, Pathology, Woman, Pharmaceutical industry

SALT LAKE CITY, June 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with GSK aimed at improving access to homologous recombination deficiency (HRD) diagnostic testing for high-grade serous ovarian cancer (HGSOC) patients.

Key Points: 
  • SALT LAKE CITY, June 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with GSK aimed at improving access to homologous recombination deficiency (HRD) diagnostic testing for high-grade serous ovarian cancer (HGSOC) patients.
  • HRD testing is an important predictive and prognostic biomarker for patients who have ovarian cancer.
  • Myriad’s MyChoice Tests determine HRD status in women with ovarian cancer.
  • Clinicians can order this test through their local pathology labs and samples are sent to Myriad Genetics.

RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

Retrieved on: 
понедельник, июня 10, 2024
Novo Nordisk, Bristol Myers Squibb, GSK, Patient, Baxter, StartX, Negotiation, Senior, LOS, Cancer, Daiichi Sankyo, Eli Lilly, Stanford University, FDA, Novartis, Medtech, Imugene, Strategic management, Pharmaceutical industry

(“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that Ryan Witt has joined the Company in the new role as Senior Vice President, Head of Corporate Strategy and Partnerships.

Key Points: 
  • (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that Ryan Witt has joined the Company in the new role as Senior Vice President, Head of Corporate Strategy and Partnerships.
  • Mr. Witt’s leadership in corporate strategy and operational experience includes sourcing, nurturing, negotiating, closing, and managing partnerships across top 25 global biopharma.
  • "I am thrilled to officially welcome Ryan as our new Senior Vice President, Head of Corporate Strategy and Partnerships,” said Shaun Bagai, CEO of RenovoRx.
  • “Ryan brings extensive corporate strategy and operational experience to this role at RenovoRx.

Election to Equinor's board of directors

Retrieved on: 
вторник, июня 4, 2024
School, Equinor, Indirect procurement, DNB, NHH, GSK, ASA, Head, Business administration, Master of Business Administration, Yara International, Security (finance), Procter & Gamble, Disclosure, Master of Science, GSK plc, SHV Holdings, University of Graz, FMCG, Stanford University, P&G, CFO, EQNR

Furthermore, the nomination committee re-elected of Jon Erik Reinhardsen as chair and Anne Drinkwater as deputy chair of the board, in addition to re-election of Jonathan Lewis, Finn Bjørn Ruyter and Haakon Bruun-Hanssen as members of the board of directors.

Key Points: 
  • Furthermore, the nomination committee re-elected of Jon Erik Reinhardsen as chair and Anne Drinkwater as deputy chair of the board, in addition to re-election of Jonathan Lewis, Finn Bjørn Ruyter and Haakon Bruun-Hanssen as members of the board of directors.
  • The current members, Rebekka Glasser Herlofsen and Tove Andersen will resign from the board of directors.
  • Board member Mikael Karlsson, who was elected as of 1 April 2024, was not up for election.
  • The election to the board of directors of Equinor ASA enters into effect from 1 July 2024 and is effective until the ordinary election of members to the board of directors in June 2025.

GSK Enters Into a Multi-Year Data Licence Agreement With Ochre Bio to Further Investigate the Drivers of Liver Disease

Retrieved on: 
среда, июня 12, 2024
Research, Medical Devices, Medical Supplies, Clinical Trials, Biotechnology, Managed Care, Health, Pharmaceutical, Science, Liver disease, Machine learning, Partnership, SVP, Hepatitis B, GSK, AI, Patient, Disease, Liver, Pharmaceutical industry

Ochre Bio, a pioneer in chronic liver disease medicine development, has today announced the start of a multi-year data licence agreement with GSK.

Key Points: 
  • Ochre Bio, a pioneer in chronic liver disease medicine development, has today announced the start of a multi-year data licence agreement with GSK.
  • The partnership will provide GSK with access to Ochre Bio’s computational biology, cellular and perfused human organ platforms to generate proprietary human liver datasets and non-exclusive access to their extensive library of historical liver data.
  • The collaboration will enable Ochre Bio and GSK to deepen the understanding of liver biology, aligned with GSK’s disease area focus in hepatology, with the aim to further prioritise and accelerate development of medicines to address liver disease.
  • Both Ochre Bio and GSK share a commitment to providing liver disease patients with more effective medicines, and believe in a data-driven approach to improve therapeutic discovery.

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

Retrieved on: 
четверг, июня 6, 2024
Biotechnology, Pharmaceutical, Oncology, Health, FDA, Genetics, Clinical Trials, Other Health, Head, NSCLC, Clinical, Multimedia, GSK, Cis, Patient, New Drug Application, Immune system, SCLC, Immunotherapy, Risk, Safety, Mesothelioma, LINK, Hazard, Teaching hospital, Bristol Myers Squibb, University, Selvaggi, Consultant, Survival, Novartis, Food, Lung cancer, Medical director, Diagnosis, ADC, Cancer, Pharmaceutical industry

CEL-SCI Corporation (NYSE American: CVM) today announced Dr. Giovanni Selvaggi, an oncology key opinion leader instrumental in successfully bringing several drugs to market has joined CEL-SCI as a Clinical Advisor.

Key Points: 
  • CEL-SCI Corporation (NYSE American: CVM) today announced Dr. Giovanni Selvaggi, an oncology key opinion leader instrumental in successfully bringing several drugs to market has joined CEL-SCI as a Clinical Advisor.
  • View the full release here: https://www.businesswire.com/news/home/20240606671425/en/
    Multikine is the first investigational pre-surgical cancer drug in newly diagnosed head and neck cancer.
  • He is also a Clinical Consultant to Tubulis GmBH for a first-in-class ADC program in solid tumors, and Clinical Strategy Senior Advisor to Alira Health.
  • Selvaggi has a passion for bringing cancer drugs to market to save lives and lead clinical research toward a cure for cancer.

US FDA Approves Expanded Age Indication for GSK’s AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk

Retrieved on: 
пятница, июня 7, 2024
Women, Infectious Diseases, Seniors, FDA, Men, Clinical Trials, Biotechnology, Pharmaceutical, Consumer, Health, Pneumonia, Multimedia, Hospital, GSK, CDC, RSV, GSK plc, Risk, Safety, Immunization, University, Chronic obstructive pulmonary disease, Systematic review, COPD, Asthma, Food, Ageing, Respiratory syncytial virus, Heart failure, Vaccine

In the US, the vaccine is currently approved for use in adults aged 60 and older and recommended by CDC/ACIP using shared clinical decision-making.

Key Points: 
  • In the US, the vaccine is currently approved for use in adults aged 60 and older and recommended by CDC/ACIP using shared clinical decision-making.
  • Professor Ann R. Falsey, University of Rochester School of Medicine, said: “I am thrilled that GSK’s RSV vaccine is now approved for adults aged 50-59 at increased risk of RSV-LRTD.
  • Many adults in this age group have underlying health conditions that place them at increased risk for serious illness with RSV infection compared with those without these conditions.
  • Trials evaluating the immunogenicity and safety of the vaccine in adults aged 18-49 at increased risk and immunocompromised adults aged 18 and over are expected to read out in H2 2024.

STUDENTS NATIONWIDE TAKE ON THE ROLE OF SPACE SCIENTISTS DURING GSK SCIENCE IN THE SUMMER™ IN COLLABORATION WITH THE FRANKLIN INSTITUTE

Retrieved on: 
четверг, июня 13, 2024
Free Library of Philadelphia, GSK, Project, Multimedia, Astronaut, Senior, Shoe, Travel, Education, STEM, Student, Workforce, Franklin Institute, Science & Education, Boy, Astrobiology, Disease, Work, Organization, Human resources, Learning, TFI, Girls, Inc., Sunrise, Boys & Girls Club, Curriculum, Pharmaceutical industry

PHILADELPHIA, June 13, 2024 /PRNewswire/ -- In a remarkable year for astronomical exploration and discovery, GSK Science in the Summer™, a free summer STEM program for students in grades 2 through 6, returns in 2024 with a new theme: "Be a Space Scientist!" Supported by GSK and led by The Franklin Institute (TFI), the nationwide program aims to reach 23,400 students across 290 organizations while providing valuable tools and TFI professional training to approximately 500 educators, helping them to develop skills to provide high-quality informal STEM experiences for youth nationwide.

Key Points: 
  • An estimated 7,000 students across Greater Philadelphia alone will experience being a space scientist this summer at over 160 locations.
  • The program will conclude with a field trip to the new Wondrous Space exhibit at The Franklin Institute later in the summer.
  • The Franklin Institute develops the GSK Science in the Summer™ curriculum, freely available at scienceinthesummer.fi.edu.
  • GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together.